Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2003
Business Overview: A global developer and manufacturer of specialized scientific instruments for drug discovery research. The company operates through three primary channels: a catalog for lower-priced items, distribution partnerships (e.g., Amersham Biosciences) for mid-range products, and a direct sales force for high-value instrumentation. The reporting period was characterized by an aggressive acquisition strategy to expand product lines in genomics and electroporation.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2003 |
Nine Months Ended Sep 30, 2003 |
Nine Months Ended Sep 30, 2002 |
|---|---|---|---|
| Total Revenues | $21,108 | $62,934 | $38,489 |
| Net Income | $986 | $2,507 | $1,709 |
| Operating Income | $1,692 | $5,033 | $2,913 |
| Gross Margin (Product) | ~49% | ~50% | ~49% |
| Cash and Equivalents | $7,577 (Sep 30, 2003) | Decreased $7.7M from Dec 31, 2002 | |
| Operating Cash Flow | $1,145 (Nine Months) | $1,785 (Nine Months) | |
| Investing Cash Flow | ($15,681) (Nine Months) | (2,291) (Nine Months) | |
| Financing Cash Flow | $6,440 (Nine Months) | (2,800) (Nine Months) | |
| Debt (Current + Long-Term) | ~$6.4M (Includes $6M bridge loan) | ~$1.1M |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 65% ($8.3M) for the quarter and 63% ($24.4M) for the nine months compared to the prior year. This growth is primarily attributable to the inclusion of revenues from recent acquisitions (BTX, GeneMachines, BioRobotics, and Genomic Solutions).
- Expense Increases: Sales and marketing expenses rose 132% for the quarter and 129% for the nine months, driven by the higher cost structure of the direct sales force utilized by acquired subsidiaries. General and administrative expenses increased 38% and 40% respectively, due to acquisitions and higher insurance costs.
- Profitability: Net income for the nine months increased to $2.5M from $1.7M in the prior year, despite a one-time arbitration charge of approximately $790,000 related to the Union Biometrica acquisition.
- Liquidity: Cash and cash equivalents declined from $15.3M to $7.6M. This reduction was driven by $15.7M in cash used for investing activities, primarily funding three major acquisitions.
- Debt Structure: The company entered into a $6.0M demand bridge loan in March 2003 and a second $6.5M bridge loan in October 2003 to fund acquisitions, anticipating a future revolving credit facility.
Guidance, Outlook, and Risks
- Acquisition Strategy: Management continues to pursue acquisitions to expand product lines and leverage distribution channels. The company is currently negotiating a revolving credit facility to replace bridge loans and fund future growth.
- Integration Risks: Significant risks exist regarding the successful integration of Genomic Solutions, BTX, GeneMachines, and BioRobotics. Failure to integrate operations, sales channels, and personnel could delay anticipated benefits.
- Legal Proceedings:
- Grindle Arbitration: The company prevailed in an arbitration with Paul D. Grindle regarding the Harvard Apparatus acquisition; the Massachusetts Superior Court confirmed the decision in July 2003.
- Union Biometrica Arbitration: The company lost an arbitration regarding escrow shares with former Union Biometrica shareholders, resulting in a final settlement payment of approximately $790,000, which was expensed in the current period.
- Market Risks: Approximately 48% of revenues are derived from international operations, exposing the company to foreign currency fluctuations. Additionally, the company relies heavily on the pharmaceutical and biotechnology industries, which are subject to funding cycles and economic downturns.
- Capital Requirements: Management expects current resources to be sufficient for at least 12 months. However, failure to secure a revolving credit facility could force the repayment of bridge loans on unfavorable terms.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating Genomic Solutions and GeneMachines, specifically regarding revenue synergies and cost reductions.
- Debt Financing: Confirm the status of the negotiations for the revolving credit facility intended to replace the $6.5M in outstanding bridge loans.
- Genomic Solutions Performance: Monitor the profitability trajectory of Genomic Solutions, which has a history of significant losses and requires substantial revenue growth to sustain profitability.
- Inventory Levels: Review inventory balances ($22.8M), which increased significantly, to assess potential obsolescence risks given the rapid technological changes in the industry.
- Legal Finality: Ensure no further appeals or legal actions are pending regarding the Union Biometrica or Grindle matters.